127553-47-3

Upstream product

• 81246-80-2 5'-O-dimethoxytrityl-2'-O-tert-butyldimethylsilyl uridine 
• 121-44-8 triethylamine 
• 15074-54-1 2-chlorophenyl dichlorophosphate 
• 15715-58-9 triethylamine carbonate 

Downstream Products

• 134009-32-8 C₆₅H₆₆ClN₄O₁₈PSi 
• 1134195-48-4 5'-O-dimethoxytrityl-2'-O-t-butyldimethylsilyluridine-3'-O-chlorophenylphosphate-5'-O-2'-O-t-butyldimethylsilyluridine 
• 1403490-81-2 C₆H₁₅N*C₁₁₉H₁₄₂Cl₄N₁₀O₃₅P₄Si₄ 
• 79537-08-9 2'-O-(tert-Butyldimethylsilyl)uridin-3'-(2-chlorophenyl)(2-cyanaethyl)phosphat 
• 2415-43-2 uridylyl-3',5'-uridine 
• 112343-27-8 C₄₄H₄₈ClN₄O₁₆PSi 

Relevant academic research and scientific papers

Design, synthesis and systematic evaluation of all possible cyclic dinucleotides (CDNs) that activate human stimulator of interferon genes (STING) variants

Cyclic dinucleotides (CDNs) are known to activate stimulator of interferon genes (STING) and induce type I interferon responses, therefor possess great potentials to be of immunotherapeutic value for cancers and infectious diseases. However, the existence

Chemical synthesis of bioactive siRNA in solution phase by using 2-(azidomethyl)benzoyl as 3′-hydroxyl group protecting group

A protecting group AZMB was introduced to ribonucleosides 3′-hydroxyl group to facilitate solution phase synthesis of siRNA. The protection and cleavage reaction were carried out in mild conditions, that is protection by acyl chloride and cleavage by triphenylphosphine. The synthesized siRNA showed good biological activity to suppress targeted superoxide dismutase gene expression.

METHOD FOR PREPARING OLIGONUCLEOTIDE

A method for preparing oligonucleotide comprising reacting the compound of Formula (1) with the compound of Formula (2) in a liquid reaction medium under the condition of condensation reaction to obtain the compound of formula (3). In the method according to the present invention, the functional groups are protected by suitable protective groups to only expose the 5′-OH of the compound of Formula (1) (OH-component) and the 3′-phosphate of the compound of Formula (2) (P-component) which are to be connected, so that the condensation reaction is carried out in a liquid reaction medium to bond the OH-component and P-component to obtain DNA or RNA short chain. The method of the present invention does not need a solid phase column and can be carried out in a liquid reaction medium. Thus, oligonucleotides can be synthesized on a large scale.

Preparation of Nucleotide Oligomer

The present invention provides a method for preparing nucleotide oligomers, including (a) coupling a nucleotide dimer or nucleotide trimer to a nucleoside attached to solid supports or to universal solid supports as a starting material; (b) sequentially coupling nucleotide monomers to the resulting structures of Step (a) to prepare a nucleotide oligomer; and (c) removing the nucleotide oligomers from the solid supports. The method of the present invention provides nucleotide oligomers having 15-20% higher purity than the conventional art. The present invention enables the efficient and inexpensive synthesis of nucleotide oligomers with high purity within a shorter period of time.

Spectroscopic and enzymatic chracterization of 2'-5' and 3'-5' RNA hexamers AACCUU synthesised by phosphotriester approach in solution using 2'-t-butyldimethylsilyl protection

Comparative 1H, 31P NMR and CD spectroscopic results and enzymatic cleavage of single stranded RNA hexamers which have identical base sequence (AACCUU) but are regioisomeric at the internucleotide phosphate linkages (2'-5', 3'-5' and their covalent hybrid) are presented. The 31P NMR results revealed significant differences in local phosphate backbone conformation among these isomers, with 2'-5' isomer exhibitingf maximum heterogeneity as compared to the 3'-5' isomer, the analogous DNA hexamer and the covalent hybrid hexamer. In contrast to this, there are no appreciable differences in the overall base-base stacking as seen in the CD spectra of 2'-5' and 3'-5' isomers. All RNA hexamers were synthesised by solution phase phosphotriester chemistry with t-butyldimethylsilyl (TBDMS) as 2'-O-protecting group. The fully protected oligorobomers were deprotected in two steps: (i) saturated anhydrous MeOH-NH3 for phosphate and amino deprotections and (ii) TBAF for removal of 2'-O-TBDMS group. Use of sat. MeOH-NH3 (instead of aq. NH3) prevents 2'-3' internucleotide phosphate migrations, chain fragmentations and 5'-terminal modifications by neighbouring group participation (NGP). The retention of isomeric integrity and absence of 5'-terminal modification in the final products was established by digestion with several nucleases.